Marshall Wace, LLP Belite Bio, Inc Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Belite Bio, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 9,486 shares of BLTE stock, worth $697,505. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,486Holding current value
$697,505% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding BLTE
# of Institutions
19Shares Held
76.1KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.2KShares$1.49 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA12.9KShares$945,8890.0% of portfolio
-
Jpmorgan Chase & CO New York, NY8.16KShares$600,1510.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il7.46KShares$548,2390.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.3KShares$316,1790.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.83B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...